24/7 Market News Snapshot 25 August, 2025 – Serina Therapeutics, Inc. (NYSE:SER)

August 25, 2025

DENVER, Colo., 25 August, 2025 (www.247marketnews.com) – (NYSE:SER) are discussed in this article.
Today saw an impressive surge for Serina Therapeutics, Inc. (SER), which opened trading at $5.69 and reached an exhilarating high of $7.15, marking a substantial increase of 26.6%. This notable spike is accompanied by strong trading volume of 533.73K shares, highlighting significant investor engagement and confidence in the company’s future. The market is closely monitoring this upward trajectory, anticipating how Serina Therapeutics will harness this momentum.

Central to this excitement is Serina’s groundbreaking investigational therapy, SER-252 (POZ-apomorphine), which aims to transform treatment options for patients suffering from advanced Parkinson’s disease. Recent feedback from a Type B meeting with the U.S. Food and Drug Administration (FDA) has provided encouragement for the advancement of SER-252 into a registrational clinical study program utilizing the 505(b)(2) New Drug Application (NDA) pathway.

CEO Steve Ledger underscored the urgent need for improved therapeutic options, stating, “People living with advanced Parkinson’s need more consistent relief from motor fluctuations, and our data to date suggest that SER-252 may reliably improve daily function.” With a strategic focus on development efficiency, the company plans to file a U.S. Investigational New Drug (IND) application in the fourth quarter of 2025, with patient dosing expected to commence in Australia soon thereafter and U.S. enrollment to begin in early 2026.

The forthcoming SER-252-1b study will adopt a rigorous randomized, double-blind, placebo-controlled design to thoroughly evaluate the safety, tolerability, and pharmacokinetics of SER-252. Leveraging the proprietary POZ Platform™, this therapy seeks to offer continuous dopaminergic stimulation (CDS) via a user-friendly subcutaneous injection. The investigation into SER-252’s potential to alleviate motor fluctuations stands to mark a significant breakthrough for individuals battling Parkinson’s disease.

In addition to SER-252, Serina Therapeutics is dedicated to expanding its portfolio of POZ-enabled small molecules, aspiring to apply similar innovative approaches for future therapies. With its commitment to advancing treatment options for neurological conditions, Serina remains at the forefront of biotech innovation, poised to make a meaningful impact in the lives of patients and the healthcare community.

Related news for (SER)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.